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A B S T R A C T
Background
The most recent syncope guideline recommends that implantable loop recorders (ILRs) are implanted in the early phase of evaluation
of people with recurrent syncope of uncertain origin in the absence of high-risk criteria, and in high-risk patients after a negative
evaluation. Observational and case-control studies have shown that loop recorders lead to earlier diagnosis and reduce the rate of
unexplained syncopes, justifying their use in clinical practice. However, only randomised clinical trials with an emphasis on a primary
outcome of specific ILR-guided diagnosis and therapy, rather than simply electrocardiogram (ECG) diagnosis, might change clinical
practice.
Objectives
To assess the incidence of mortality, quality of life, adverse events and costs of ILRs versus conventional diagnostic workup in people
with unexplained syncope.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, 2015), MEDLINE, EMBASE, ClinicalTrials.gov
and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal in April 2015. No
language restriction was applied.
Selection criteria
We included all randomised controlled trials of adult participants (i.e. ≥ 18 years old) with a diagnosis of unexplained syncope
comparing ILR with standard diagnostic workup.
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Data collection and analysis
Two independent review authors screened titles and abstracts of all potential studies we identified as a result of the literature search,
extracted study characteristics and outcome data from included studies and assessed risk of bias for each study using the criteria
outlined in the Cochrane Handbook for Systematic Reviews of Interventions. We contacted authors of trials for missing data. We analysed
dichotomous data (all-cause mortality and aetiologic diagnosis) as risk ratios (RR) with 95% confidence intervals (CI). We used the
Chi2 test to assess statistical heterogeneity (with P < 0.1) and the I² statistic to measure heterogeneity among the trials. We created a
’Summary of findings’ table using the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta-analyses
for the prespecified outcomes.
Main results
We included four trials involving a total of 579 participants. With the limitation that only two studies reported data on mortality and
none of them had considered death as a primary endpoint, the meta-analysis showed no evidence of a difference in the risk of long-
term mortality between participants who received ILR and those who were managed conventionally at follow-up (RR 0.97, 95% CI
0.41 to 2.30; participants = 255; studies = 2; very low quality evidence) with no evidence of heterogeneity. No data on short term
mortality were available. Two studies reported data on adverse events after ILR implant. Due to the lack of data on adverse events in
one of the studies’ arms, a formal meta-analysis was not performed for this outcome.
Data from two trials seemed to show no difference in quality of life, although this finding was not supported by a formal analysis due
to the differences in both the scores used and the way the data were reported. Data from two studies seemed to show a trend towards a
reduction in syncope relapses after diagnosis in participants implanted with ILR. Cost analyses from two studies showed higher overall
mean costs in the ILR group, if the costs incurred by the ILR implant were counted. The mean cost per diagnosis and the mean cost
per arrhythmic diagnosis were lower for participants randomised to ILR implant.
Participants who underwent ILR implantation experienced higher rates of diagnosis (RR (in favour of ILR) 0.61, 95% CI 0.54 to
0.68; participants = 579; studies = 4; moderate quality evidence), as compared to participants in the standard assessment group, with
no evidence of heterogeneity.
Authors’ conclusions
Our systematic review shows that there is no evidence that an ILR-based diagnostic strategy reduces long-termmortality as compared to
a standard diagnostic assessment (very low quality evidence). No data were available for short-term all-cause mortality. Moderate quality
evidence shows that an ILR-based diagnostic strategy increases the rate of aetiologic diagnosis as compared to a standard diagnostic
pathway. No conclusive data were available on the other end-points analysed.
Further trials evaluating the effect of ILRs in the diagnostic strategy of people with recurrent unexplained syncope are warranted. Future
research should focus on the assessment of the ability of ILRs to change clinically relevant outcomes, such as quality of life, syncope
relapse and costs.
P L A I N L A N G U A G E S U M M A R Y
Implantable loop recorder versus conventional diagnostic assessment for people with unexplained recurrent fainting
Review question
The aim of this study was to assess the evidence about potential benefits and harms of implantable loop recorders (ILRs) compared to
standard diagnostic assessment for people with unexplained recurrent faints or blackouts.
Background
Syncope (commonly referred to as fainting or blackout) is a temporary loss of consciousness due to momentary lack of blood flow to the
brain. It is characterised by rapid onset, short duration and spontaneous complete recovery. Syncope may be the common presentation
of different conditions, spanning from harmless to life-threatening, such as cardiac arrhythmias (i.e. sudden increased or decreased
heartbeat). The electrocardiogram registration during syncope allows physicians either to confirm or exclude an arrhythmia as the
mechanism of syncope.
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ILRs are pen drive-sized devices implanted under the skin. They have a retrospective (loop) memory that continuously records and
deletes the patient’s electrocardiogram. ILR implant is suggested in the early phase of the evaluation of syncope patients.
The aim of this systematic review was to compare the potential benefits and harms of ILRs with conventional diagnostic assessment in
people with unexplained syncope.
Study characteristics
We searched scientific databases and found four randomised controlled trials (clinical studies where people are randomly put into one
of two or more treatment groups) including 579 adults, which met our inclusion criteria. This review includes evidence identified up
to April 2015.
Key results
All-cause mortality (death from any cause) was no different in people who received the ILR. Loop recorders do not seem to change
quality of life, although people with ILR had a significantly higher rate of diagnosis compared to participants in the standard assessment
group. Moreover, data seem to show a trend towards a reduction in syncope recurrences after diagnosis in people implanted with ILR.
Finally, costs were higher in the group of participants in which the ILR was implanted but the cost per diagnosis and the cost to diagnose
an arrhythmia were much lower for participants randomised to ILR implant.
Quality of the evidence
There was low quality evidence that ILR does not change mortality if compared to a standard diagnostic assessment of people with
syncope. There was moderate quality evidence that ILR increases the rate of diagnosis if compared to a standard diagnostic assessment.
Future research is needed in order to clarify if ILRs can improve quality of life and reduce syncope recurrences and costs.
All the included studies were funded: two of them by scientific societies, the remaining were partially supported by the ILR’s manufac-
turers.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Implantable loop recorders compared with conventional diagnostic workup for unexplained syncope
Patient or population: people with unexplained recurrent syncope
Settings: any
Intervention: implantable loop recorders
Comparison: conventional diagnostic workup
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Conventional diagnos-
tic workup
Implantable loop
recorders
All- cause short- term
mortality
See comment See comment Not est imable 0 See comment No data on short-term
mortality were available
All- cause long- term
mortality
Study population RR 0.97 (0.41 to 2.30) 255
(2 RCTs)
⊕©©©
very low1,2,3
71 per 1000 67 per 1000
(28 to 161)
Other adverse events See comment See comment Not est imable 447
(2 RCTs)
See comment No complicat ions were
observed following the
procedure in either of
the studies. Due to the
lack of data on adverse
events in the control
group in one of the stud-
ies, we did not perform
a formal meta-analysis
for this outcome
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Quality of life See comment See comment Not est imable 279
(2 RCTs)
See comment Due to the dif ferences
in the scores used and
the way data were re-
ported, we could not
perform a formal meta-
analysis. Please, see
footnote4
Syncope relapse See comment See comment Not est imable 507
(3 RCTs)
See comment Two studies showed a
signif icant reduct ion in
syncope recurrence af -
ter ECG-directed treat-
ment. Please, see foot-
note5.
Economic costs See comment See comment Not est imable 261
(2 RCTs)
See comment Given the high hetero-
geneity in both the re-
sults and the cost-as-
sessments across the
studies, we were un-
able to perform a quan-
t itat ive analysis. Please
see footnote6
Aetiologic diagnosis Study population RR 0.61 (0.54 to 0.68) 579
(4 RCTs)
⊕⊕⊕©
moderate1
125 per 1000 77 per 1000
(68 to 85)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk Ratio, RCT : Randomised controlled trial.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.5
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1 Downgraded by one level for high risk of bias in the included studies.
2,3 Downgraded by two levels for very serious risk of imprecision, as the CI fails to exclude important benef its or important
harms and a small number of events have been observed.
4 In one trial quality of lif e was measured by the 12-item short form of the Medical Outcomes Quest ionnaire (SF-12) and a
visual analogue scale (VAS). A f irst report showed that quality of lif e was sim ilar in both groups. At the 18-month follow-up
there was a trend towards improved quality of lif e in the ILR group compared with that of controls with signif icant increases
observed in VAS of general well being (P = 0.03), no change was noted in SF-12 scores. In the second trial an analysis of
quality of lif e using the 36-Item Short Form Health Survey (SF-36) quest ionnaire was performed at baseline, six months and
af ter 14 months’ follow-up. There were no dif ferences between the main composite scores suggest ive of general physical
and psychological well being. While there were no dif ferences in physical funct ioning (i.e. intensity of exercise or walking
distance), social funct ioning or mental health between the two groups, there was a signif icant ly better score in “role lim itat ions
due to physical problems” in the ILR group. The scores for “role lim itat ions due to emotional problems” were not stat ist ically
dif f erent between the two groups.
5 One of the studies was a cross-over trial, and data f rom this study could not be analysed, as the part icipants were of fered
cross-over to the alternat ive strategy af ter the f irst syncope recurrence if no diagnosis was made. Two studies showed
signif icant reduct ions in syncope recurrence af ter treatment. Due to the dif ferences in the way the data were reported, a
formal meta-analysis could not be performed for this outcome.
6 In the f irst study the ILR’s cost was not included in the analysis. Overall mean costs were lower in the ILR group than in the
convent ional management group, without stat ist ical signif icance. In the second study the mean cost of the invest igat ion with
the convent ional strategy was signif icant ly less than invest igat ion with the primary strategy of monitoring but the cost per
diagnosis was signif icant ly greater.
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B A C K G R O U N D
Description of the condition
Syncope is defined as “a transient loss of consciousness due to tran-
sient global cerebral hypoperfusion characterised by rapid onset,
short duration and spontaneous complete recovery” (Moya 2009).
It is a common symptom that can be remarkably debilitating and
is associated with high healthcare costs (Sun 2013). Its true inci-
dence is difficult to estimate due to variation in definition, differ-
ences in population prevalence and under-reporting in the general
population. In the Framingham offspring study, 44% of partici-
pants with an episode of syncope reported that they did not seek
medical advice (Soteriades 2002) and the proportion of partici-
pants not seeking medical evaluation in the younger population
was much higher (Ganzeboom 2003; Serletis 2006). An estimated
40% of people faint at least once in their lifetime (Ganzeboom
2006). The median peak of first syncope is around 15 years, with
a sharp increase after 70 years (Soteriades 2002). Data from the
USA and Europe show that syncope accounts for between 1%
to 3% of hospital emergency department (ED) visits (Soteriades
2002) and up to 6% of hospitalisations (Gendelman 1983).
From a pathophysiological standpoint, the causes of syncope are
typically divided between cardiovascular (due to brady- or tach-
yarrhythmias or structural heart disease) and non-cardiac, which
include orthostatic hypotension and reflex syncope (vasovagal, sit-
uational and carotid sinus syndrome) (Moya 2009; Reed 2015).
Vasovagal syncope is themost common cause of syncope for all age
groups, but cardiac causes become more common with advancing
age. The prognosis of syncope patients is heterogeneous (Solbiati
2015a) and depends on whether the aetiology is cardiac or non-
cardiac.While the latter is associatedwith a benignmortality prog-
nosis, similar to that of syncope-free control individuals, people
with cardiac syncope have a one-year overall mortality rate of up
to 30% (Eagle 1985; Kapoor 1983; Soteriades 2002), which is
mainly due to coronary artery disease, myocardial infarction and
cerebrovascular disease (Soteriades 2002). For people aged over 65
years, cardiovascular disease in clinical history, syncope without
prodromes and abnormal electrocardiogram (ECG) are indepen-
dent predictors of one-year cardiovascular and non-cardiovascular
mortality (Colivicchi 2003). However, their true relation to syn-
cope outcomes and their role in short-term risk stratification is
debated (Costantino 2014A; Costantino 2014B),
In the absence of more recent epidemiological data, the high his-
toric mortality associated with cardiac syncope justifies the large
amount of energy, time and money spent on the evaluation of syn-
cope. Nevertheless, approximately 5% to 30% of syncopes remain
unexplained after intensive diagnostic evaluation (EGSYS-2 2006;
Sarasin 2001; Shen 2004). On the other hand, despite its benign
prognosis, even recurrent vasovagal syncope may lead to a signif-
icant decrease in quality of life because of trauma, and psycho-
logical, driving, employment and financial implications. There-
fore, many low-risk syncope patients require extensive investiga-
tion or more aggressive treatments in selected cases (Costantino
2015). In case treatment is deemed necessary because of the high
burden of symptoms, both pharmacological (beta-blockers, flu-
drocortisone, alpha-adrenergic agonists, selective serotonin reup-
take inhibitors, angiotensin-converting enzyme inhibitors, disopy-
ramide, anticholinergic agents or salt tablets) and dual-chamber
pacemaker treatment have been proposed (Kuriachan 2008; Raj
2013; Solbiati 2014). However, a systematic review of randomised
controlled trials (RCTs) of pharmacological or dual-chamber pace-
maker treatment in reflex syncope showed that existing studies are
small and heterogeneous in control treatments, outcomes consid-
ered and results, thus suggesting that evidence to support the use
of any of these for vasovagal and carotid sinus syncope is weak
(Romme 2011).
Description of the intervention
The ECG registration during syncope allows physicians either
to confirm or exclude an arrhythmia as the mechanism of syn-
cope (Krahn 2004). ECGmonitoring is the most common proce-
dure for diagnosing intermittent arrhythmias. Several systems of
ECG ambulatory monitoring are currently available: in-hospital
monitoring, conventional ambulatory Holter monitoring, event
recorders, external or implantable loop recorders, and remote (at
home) telemetry. In people with frequent symptoms, relatively
short-term (one month) non-invasive ECGmonitoring (e.g. with
either event recorders or external loop recorders)may suffice.How-
ever, syncopal episodes usually occur less frequently, and for this
reason long-term implantable loop recorders (ILRs) have been de-
veloped.
ILRs are pen drive-sized devices implanted subcutaneously under
local anaesthesia in the left side of the chest and have a battery
life of up to 36 months. They have no intravascular leads, record-
ing a bipolar ECG signal from small electrodes on either end of
the devices. ILRs have a retrospective (loop) memory that con-
tinuously records and deletes the patient’s ECG. They include a
patient-activation function that allows the patient or a bystander
to activate ECG storage in case of syncope and an auto-activation
feature capturing pre-defined arrhythmias (Krahn 2004). Like all
implanted devices, ILRs also carry the risk of pocket infections
that resolve with device explantation. This complication, which
can occur either in the peri-procedural phase or late during the
follow-up, was reported in 1% to 5% of patients (Brignole 2006;
Krahn 1999).
How the intervention might work
The ILR may be most useful in people with infrequent symp-
toms and a suspected arrhythmia in whom noninvasive testing
is negative or inconclusive. In such people, transient bradycar-
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dia is frequently found to be responsible, although infrequent
tachyarrhythmias are also documented. Symptoms associated with
normal sinus rhythm (thus excluding arrhythmias) are also a com-
mon finding (Krahn 1999).
Many studies have analysed the utility of ILRs in recurrent un-
explained or high risk syncope. These studies suggest that early
use of the ILR provides more and earlier diagnoses and could help
in selecting people who might benefit from pacemaker therapy
(Brignole 2006; EGSYS-2 2006; Krahn 1999; Krahn 2004).
Why it is important to do this review
Since its introduction, the ILR has become the investigative tool
of choice in recurrent unexplained syncope following negative ini-
tial investigations. The European Society of Cardiology’s (ESC)
guidelines now recommend that ILRs are implanted in the early
phase of evaluation of people with recurrent syncope of uncer-
tain origin in the absence of high-risk criteria, and in high-risk
patients after a negative evaluation (Moya 2009). According to
ESC guidelines, ILR implant may also be indicated to assess the
contribution of bradycardia in people with suspected or certain
neurally-mediated syncope, presenting with frequent or traumatic
syncopal episodes, before considering permanent pacing, and in
people with transient loss of consciousness of uncertain syncopal
origin in order to exclude an arrhythmic aetiology.
In a previous narrative review, Parry 2010 searched for studies in-
volving the ILR as a part of the diagnostic workup of recurrent un-
explained or neurally-mediated syncope. Most were small obser-
vational studies and, even if a systematic literature search was per-
formed, no attempt to combine the available data was made. Ob-
servational and case-control studies have shown that loop recorders
lead to earlier diagnosis and reduce the rate of unexplained syn-
copes, justifying their use in clinical practice. However, only RCTs
with emphasis on a primary outcome of specific ILR-guided di-
agnosis and therapy, rather than simply ECG diagnosis, might
change clinical practice.
O B J E C T I V E S
To assess the incidence of mortality, quality of life, adverse events
and costs of ILRs versus conventional diagnostic workup in people
with unexplained syncope.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs comparing ILR to conventional diagnostic
workup in people with unexplained syncope. We included studies
reported as full-text articles, those published as abstract only, and
unpublished data. We excluded cluster-RCTs to avoid the risk of
introducing biases (Higgins 2011a).
Types of participants
We included studies enrolling adult participants (i.e. ≥ 18 years
old) with a diagnosis of unexplained syncope (i.e. syncope, as de-
fined in the single studies, without a definite cause after an initial
evaluation). We excluded studies that enrolled only paediatric pa-
tients (i.e. < 18 years old); we included studies enrolling a mixed
population (i.e. studies in which most (i.e. > 80%) of the partici-
pants were adults, even if the age range of the included participants
was below 18 years). We also excluded studies including only par-
ticipants with a history of heart disease or ECG abnormalities.
Types of interventions
We included trials comparing ILR with standard diagnostic
workup (i.e. any other tests or clinical follow-up aimed at identi-
fying the cause of syncope).
Types of outcome measures
Primary outcomes
1. Short (i.e. within 30 days) and long-term all-cause
mortality.
2. Other adverse events (cardiopulmonary resuscitation,
intensive care unit admittance, major trauma, acute myocardial
infarction, pulmonary embolism, major bleeding, aortic
dissection, ILR-related adverse events requiring either explant or
treatment).
3. Quality of life during follow-up (as defined in the single
studies).
Secondary outcomes
1. Syncope relapse (i.e. a second syncope recurrence after
randomisation).
2. Economic costs.
3. Aetiological diagnosis.
Search methods for identification of studies
Electronic searches
We identified trials through systematic searches of the following
bibliographic databases:
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1. Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library Issue 3 of 12, 2015);
2. MEDLINE, 1946 to April week 3 2015 (Ovid);
3. EMBASE, 1974 to 2015 April 24 (Ovid).
We adapted the preliminary search strategy forMEDLINE (Ovid)
to searches of other databases (Appendix 1). We applied the
Cochrane sensitivity-maximising RCT filter (Lefebvre 2011) to
MEDLINE and an adaptation of it to EMBASE.
Also, we conducted a search of ClinicalTri-
als.gov (www.ClinicalTrials.gov) and theWorld Health Organiza-
tion (WHO) International Clinical Trials Registry Platform (IC-
TRP) Search Portal (http://apps.who.int/trialsearch/) (Appendix
1).
We searched all databases from the earliest date available in each
database to the present, andwe imposed no restriction on language
of publication. Searches were performed for all databases on 27
April 2015.
Searching other resources
We checked reference lists of all included studies, international
guidelines (Huff 2007; Moya 2009; Sheldon 2011) and review
articles (Parry 2010) for additional references. We searched rel-
evant manufacturers’ websites for trial information (Medtronic;
St. Jude) on 27 April 2015 as well.
Data collection and analysis
Selection of studies
Two review authors (FD, AG) independently screened titles and
abstracts of all potential studies we identified as a result of the liter-
ature search, and coded them as ’retrieve’ (eligible or potentially el-
igible/unclear) or ’do not retrieve’. If there were any disagreements,
a third review author (MS) arbitrated. We retrieved the full-text
study reports/publications coded ’retrieve’. Two review authors
(FD, AG) independently screened the full-text articles and identi-
fied studies for inclusion, and identified and recorded reasons for
exclusion of the ineligible studies. We resolved any disagreements
through discussion or, if required, we consulted a third review
author (MS). We identified and excluded duplicates and collated
multiple reports of the same study so that each study, rather than
each report, was the unit of interest in the review. We recorded the
selection process in sufficient detail to complete a PRISMA flow
diagram (Liberati 2009) and ’Characteristics of excluded studies’
table.
Data extraction and management
We used a data collection form for study characteristics and out-
come data which was piloted on at least one study in the review.
Two review authors (MS, GCo) independently extracted study
characteristics from the included studies. We resolved any dis-
agreements through discussion or, if required, we consulted a third
review author (GCa). We extracted the following study character-
istics.
1. Methods: study design, total duration of study, number of
study centres and location, study setting, withdrawals and date of
study.
2. Participants: number (N), mean age, age range, gender,
severity of condition, known cardiovascular disease, ECG
abnormalities, inclusion and exclusion criteria.
3. Interventions: type of ILR (intervention), type of
comparison.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (MS, GCo) independently extracted outcome
data from the included studies. We resolved disagreements by con-
sensus or by involving a third review author (GCa). One review
author (MS) transferred data into the Review Manager (RevMan)
(RevMan 2014) file. We double-checked that data were entered
correctly by comparing the data presented in the systematic re-
view with the study reports. A second review author (GCa) spot-
checked study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (MS, GCo) independently assessed risk of bias
for each study using the criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011b). We
resolved any disagreements by discussion or by involving another
review author (GCa). We assessed the risk of bias according to six
domains: random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome as-
sessment, incomplete outcome data, and selective outcome report-
ing.
We graded each potential source of bias as either ’high’, ’low’ or
’unclear’ and provided a justification for our judgment in the ’Risk
of bias’ table. We summarised the risk of bias judgements across
different studies for each of the domains listed.
Within a trial, we gave a summary assessment of low risk of bias
when there was a low risk of bias for all domains, unclear risk
of bias when there was an unclear risk of bias for one or more
domains, or high risk of bias when there was a high risk of bias for
one or more domains.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
We used the following criteria for the risk of bias judgements:
1. Random sequence generation
i) Low risk of bias - adequate generation of the allocation
sequence (e.g. computer-generated random numbers, table of
random numbers or similar);
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ii) Unclear risk of bias - unclear about whether the
allocation was adequately generated (e.g. where the method of
sequence generation is not described or not described in
sufficient detail to allow a definite judgement);
iii) High risk of bias - inadequate generation of the
allocation sequence (e.g. sequence generation by the date of
admission, clinical record number and odd/even status).
2. Allocation concealment
i) Low risk of bias - adequate concealment of the
allocation (e.g. sequentially numbered, sealed, opaque envelopes
or centralised or pharmacy-controlled randomisation);
ii) Unclear risk of bias - unclear about whether the
allocation was adequately concealed (e.g. where the method of
concealment is not described or not described in sufficient detail
to allow a definite judgement);
iii) High risk of bias - inadequate allocation concealment
(e.g. predictable methods such as using an open allocation
schedule as well as non-opaque, non-sealed or non-sequential
numbered envelopes).
3. Blinding of participants and personnel
i) Low risk of bias - adequate blinding of participants
and personnel (e.g. using sham ILR in the control group or
performing sham diagnostic tests to patients in the intervention
group);
ii) Unclear risk of bias - unclear about whether
participants and personnel were blind to diagnostic strategy (e.g.
whether blinding was not described or not described in sufficient
detail to allow a definite judgement);
iii) High risk of bias - inadequate blinding of participants
and personnel (e.g. participants or personnel, or both, were not
blinded to the intervention group allocation).
4. Blinding of outcome assessment
i) Low risk of bias - adequate blinding of outcome
assessors (e.g. outcome assessors unaware of the intervention
group allocation);
ii) Unclear risk of bias - unclear about whether outcome
assessors were blind to diagnostic strategy (e.g. whether blinding
was not described or not described in sufficient detail to allow a
definite judgement);
iii) High risk of bias - inadequate blinding of outcome
assessors (e.g. outcome assessors were not blinded to the
intervention group allocation).
5. Incomplete outcome data
i) Low risk of bias - adequate reporting of withdrawals,
dropouts and protocol deviations (e.g. no missing outcome data;
reasons for missing outcome data unlikely to be related to true
outcome; missing outcome data balanced in numbers across
intervention groups; missing data have been imputed using
appropriate methods);
ii) Unclear risk of bias - insufficient reporting of
attrition/exclusions to permit judgement (e.g. number
randomised not stated, no reasons for missing data provided);
iii) High risk of bias - reason for missing outcome data
likely to be related to true outcome (e.g. either imbalance in
numbers or reasons for missing data across intervention groups;
“as-treated” rather than “intention-to-treat” analysis done, with
substantial departure of the intervention received from that
assigned at randomisation; potentially inappropriate application
of simple imputation).
6. Selective outcome reporting
i) Low risk of bias - adequate reporting of the study
outcomes (e.g. the study protocol was available and all of the
study’s pre-specified outcomes that were of interest in the review
were reported in the pre-specified way);
ii) Unclear risk of bias - insufficient information to
permit judgement;
iii) High risk of bias - inadequate reporting of the study
outcomes (e.g. not all of the study’s pre-specified primary
outcomes have been reported; one or more primary outcome was
reported using measurements, analysis methods or subsets of the
data that were not pre-specified; one or more reported primary
outcomes were not pre-specified (unless clear justification for
their reporting was provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review were
reported incompletely so that they could not be entered in a
meta-analysis; the study report failed to include results for a key
outcome that would have be expected to have been reported for
such a study).
Assessment of bias in conducting the systematic
review
We conducted the Cochrane review according to the published
Cochrane protocol and reported any deviations in the ’Differ-
ences between protocol and review’ section of the review (Solbiati
2015b).
Measures of treatment effect
We analysed dichotomous data (all-cause mortality and aetiologic
diagnosis) as risk ratios (RR) with 95% confidence intervals (CI).
We had planned to analyse continuous data (quality of life and
economic costs) as mean difference (MD) or, when studies used
different scales of measurements, standardised mean difference
(SMD) with 95% CI.
Unit of analysis issues
We included RCTs in which the individual is randomised. We
excluded cluster-RCTs to avoid the risk of introducing biases (
Deeks 2011).
Dealing with missing data
We contacted investigators in order to obtain missing numerical
outcome data where possible.
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We contacted the authors of one trial published in abstract form re-
questing additional information on the trial design andmethodol-
ogy, clarification regarding data discrepancies, further detail about
patient demographics or additional data, or both. The trial au-
thors responded that the trial was being published in full in a
few weeks, and we have been able to obtain data from that report
(Sulke 2015).
We contacted a further trial author in order to clarify the data on
mortality provided in the published report but we got no answer
and we have not been able to include the study in that outcome
analysis (Podoleanu 2014).
We had planned to explore the impact of including studies with
missing data by a sensitivity analysis. Due to the small number of
included studies we were unable to do so.
Assessment of heterogeneity
We used the Chi2 test to assess statistical heterogeneity (with P <
0.1) and the I² statistic to measure heterogeneity among the trials
(Higgins 2003). We would have reported and explored possible
causes of heterogeneity by prespecified subgroup analysis if we had
identified substantial heterogeneity (I2 statistic > 50%). Since we
found no heterogeneity, we did not perform subgroup analyses.
Assessment of reporting biases
We had planned to create and examine a funnel plot to explore
possible small study biases for the primary outcomes. Due to the
small number of included studies, we have not been able to do so
(Sterne 2011).
Data synthesis
We undertook meta-analyses with the RevMan 2014 software,
using a fixed-effects model, as no heterogeneity was found. We
included all studies in themain analyses irrespective of risk of bias.
Within each included trial, we analysed all participants in the
treatment groups to which they had been randomised. One study
reported data from a cross-over trial (Krahn 2001). As suggested
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011c), in order to avoid carry-over, we included only
data from the first period.
Subgroup analysis and investigation of heterogeneity
If sufficient data existed, we aimed to conduct the following sub-
group analyses.
1. Type of ILR implanted.
2. Percentage of participants identified as having a cardiac
cause of syncope at follow-up.
3. Percentage of participants with known cardiovascular
disease or ECG abnormalities.
We planned to use the following outcomes in subgroup analyses.
1. All-cause mortality.
2. Other adverse events (cardiopulmonary resuscitation,
intensive care unit admittance, major trauma, acute myocardial
infarction, pulmonary embolism, major bleeding, aortic
dissection).
3. Quality of life.
We planned to use the formal test for subgroup interactions in
RevMan 2014, but data were insufficient to do so.
Sensitivity analysis
We planned to perform sensitivity analyses by excluding studies
with high and unclear risk of bias and studies published only as
abstracts, but the data were limited due to the small number of
included studies.
Summary of findings
We created a ’Summary of findings’ table (Schünemann 2011a)
using the following outcomes:
1. short- (i.e. within 30 days) and long-term all-cause
mortality;
2. other adverse events (cardiopulmonary resuscitation,
intensive care unit admittance, major trauma, acute myocardial
infarction, pulmonary embolism, major bleeding, aortic
dissection, ILR-related adverse events requiring either explant or
treatment);
3. quality of life (as defined in the single studies);
4. syncope relapse;
5. economic costs;
6. aetiological diagnosis.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of a body of evidence as it relates to the stud-
ies which contribute data to the meta-analyses for the prespeci-
fied outcomes. We used methods and recommendations described
in Section 8.5 (Higgins 2011b) and Chapter 12 (Schünemann
2011b) of the Cochrane Handbook for Systematic Reviews of Inter-
ventions. We justified all decisions to down- or up-grade the qual-
ity of studies using footnotes and we made comments to aid the
reader’s understanding of the review where necessary.
R E S U L T S
Description of studies
Results of the search
We identified 2912 de-duplicated references. By reviewing titles
and abstracts, we excluded 2904 references, leaving eight records
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as potentially eligible, two published in abstract form and six as
full texts. One of these was excluded after full-text review, in ac-
cordance with our exclusion criteria. We found one additional
reference after contact with the authors of one trial published in
abstract form. These eight reports included four trials and we in-
cluded them in our analysis (Figure 1).
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Figure 1. Study flow diagram.
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Searches of clinical trial registers provided references to two addi-
tional published protocols. No published results were found for
either of them. The contact information for one was unavailable
and we were not able to find any recent publication for the author
on either PubMed or Scopus. We emailed the second contact for
information about the trial. He answered that the trial had never
started.
Included studies
We analysed four studies, with a total of 579 participants (Farwell
2006; Krahn 2001; Podoleanu 2014; Sulke 2015). Two studies
included participants with either recurrent syncope or a single
traumatic syncopal episode (Krahn 2001; Podoleanu 2014). Two
studies included only participants with recurrent syncope (Farwell
2006; Sulke 2015). All the studies excluded participants with
known or suspected cardiac disease as the cause of syncope.
The studies were published from 2001 to 2015. One of them was
conducted in Canada (Krahn 2001) and three in Europe: two in
the UK (Farwell 2006; Sulke 2015) and one in France (Podoleanu
2014); all of them were single centre studies. Mean follow-up
ranged from one year (Krahn 2001) to 20 months (Sulke 2015).
The number of participants enrolled in each study varied between
60 (Krahn 2001) and 246 (Sulke 2015). The percentage of men in
each study varied between 40 (Sulke 2015) and 55 (Krahn 2001)
and the mean age of the population recruited varied between 66
(Krahn 2001; Podoleanu 2014) and 74 years (Farwell 2006).
Medtronic Reveal and Reveal Plus were the ILRs implanted in
three of the studies (Farwell 2006; Krahn 2001; Podoleanu 2014);
participants in the last study (Sulke 2015) were implanted with
the Transoma Sleuth ILR. Participants in the control group un-
derwent conventional management by the attending physician in
two studies (Farwell 2006; Podoleanu 2014) and a two- to four-
week period of monitoring with an external loop recorder, fol-
lowed by tilt table, and electrophysiological testing in one study
(Krahn 2001). The latter was designed as a cross-over study and
patients were offered cross-over to the alternate strategy if the as-
signed strategy did not provide a diagnosis. Finally, participants
from one study were randomised into four groups: 1) immediate
implant of the ILR without hospital admission; 2) ILR and at-
tendance at a dedicated syncope clinic for follow-up within two
weeks; 3) syncope clinic group; 4) conventional management by
the referring physician (Sulke 2015). The management of the par-
ticipants in the conventional management arm of three studies
(Farwell 2006; Podoleanu 2014; Sulke 2015) had not been stan-
dardised and was left to the referring physician’s discretion.
Two studies were partially funded by the ILR manufacturers (
Farwell 2006; Sulke 2015); the others received grants from both
the Société Francaise de Cardiologie (Podoleanu 2014) and the
Heart and Stroke Foundation of Ontario (Krahn 2001).
Tables of Characteristics of included studies show detailed descrip-
tions of the studies.
Excluded studies
We excluded one trial from the review following full-text eligibility
assessment (Da Costa 2013). The study met one of the exclusion
criteria, as only people with ECG abnormalities (i.e. any bundle
branch block or QRS greater or equal to 120 ms) were enrolled
(see Characteristics of excluded studies).
Risk of bias in included studies
We give a description of the risk of bias for individual studies
in the Characteristics of included studies tables. We deemed all
the studies to be at a high risk of bias, as none of them blinded
participants, personnel or outcome assessors to the intervention
group allocation.
We give a summary of the risk of selection bias, performance and
detection bias, attrition bias and reporting bias below. See Figure
2 and Figure 3 for details.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Risk of bias arising from the method of generation of the ran-
dom sequence was considered low in three trials (Farwell 2006;
Podoleanu 2014; Sulke 2015). Risk of bias from the method of
concealment of the allocation was considered low in one study
(Farwell 2006) and unclear in two studies (Podoleanu 2014; Sulke
2015), as the method of concealment was not described.
In one included study, the study authors did not describe the
method of sequence generation or allocation concealment,making
the risk of selection bias unclear. However, the characteristics of
each group were similar at baseline (Krahn 2001).
Blinding
None of the studies blinded participants or personnel to the inter-
vention group allocation. There was inherent difficulty blinding
the interventions, because the intervention required a procedure
and long-term device management. Due to the lack of blinding,
the included studies had a high risk of performance bias.
Because outcome assessors were also not blinded to the interven-
tion group allocation, the risk of detection bias was also high in
all the studies.
Incomplete outcome data
Risk of attrition bias was rated as low in all the trials. In two of
them (Krahn 2001; Podoleanu 2014) no participant was lost to
follow-up; one study (Farwell 2006) balanced missing outcome
data in numbers across intervention groups.
In one study (Sulke 2015) five participants declined ILR implan-
tation after enrolment and one participant requested to have his
ILR explanted at eight months due to intolerance; analysis was by
intention-to-treat, and the absence of outcome data was consid-
ered to be unrelated to the true outcome.
Selective reporting
Only one of the studies published the protocol in advance (Sulke
2015). This study was considered at high risk of bias as the cost
analysis, which was one of the pre-defined outcomes, was not
reported in the published reports. Another trial was considered at
high risk of bias (Podoleanu 2014) because the results of the cost
analysis, which was one of the study’s aims, were not reported in
the study.
We considered two trials (Farwell 2006; Krahn 2001) to have
an unclear risk of reporting bias as the study protocol was not
available.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings for the main comparison. Implantable loop recorder
versus conventional diagnostic workup for unexplained recurrent
syncope
See Summary of findings for the main comparison for the main
comparison.
Primary outcomes
All-cause mortality
Two studies (255 participants) reported data on mortality at one
year (Krahn 2001) and 18 months (Farwell 2006).
Overall, there was no evidence of a difference in the risk of mor-
tality between participants who received ILR and those who were
managed conventionally at long-term follow-up (9/128 versus 9/
127; RR 0.97, 95% CI 0.41 to 2.30; participants = 255; studies
= 2; very low quality evidence) with no evidence of heterogeneity
(Analysis 1.1; Figure 4).
Figure 4. Forest plot of comparison: 1 ILR vs SA, outcome: 1.1 All-cause mortality.
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No data on short-term mortality were available.
Other adverse events
Two studies (Farwell 2006; Sulke 2015) reported data on adverse
events after ILR implant. No complications were observed follow-
ing the procedure in either of the studies. We did not perform a
formal meta-analysis for this outcome due to the lack of data on
adverse events in the control group (i.e. both the syncope clinic
and conventional management arms) in Sulke 2015.
Quality of life
Two trials analysed quality of life (Farwell 2006; Podoleanu 2014).
Farwell 2006 measured quality of life by the 12-item short form
of theMedical Outcomes Questionnaire (SF-12) and a visual ana-
logue scale (VAS) at induction and at 6, 12 and 18 months. A
first report showed that quality of life was similar in both groups.
At the 18-month follow-up there was a trend towards improved
quality of life in the ILR group compared with that of the control
group, with significant increases observed in VAS of general well
being (P = 0.03). No change was noted in SF-12 scores.
Podoleanu 2014 performed an analysis of quality of life using the
36-Item Short FormHealth Survey (SF-36) questionnaire at base-
line, six months and after 14 months of follow-up. There were
no differences between the main composite scores, suggestive of
general physical and psychological well being. While there were
no differences in physical functioning (i.e. intensity of exercise or
walking distance), social functioning ormental health between the
two groups, there was a significantly better score in “role limita-
tions due to physical problems” in the ILR group. The scores for
“role limitations due to emotional problems” were not statistically
different between the two groups.
Due to the differences in both the scores used and the way data
were reported, we could not perform a formal meta-analysis for
this outcome.
Secondary outcomes
Syncope relapse
Three studies reported a second recurrence of syncope after ran-
domisation (Farwell 2006; Krahn 2001; Sulke 2015). One of
them, Krahn 2001, was a cross-over trial and it evaluated syn-
cope recurrences after both the primary and the secondary strat-
egy, leading to a possible carry-over.We could not analyse the data
from this study, as the participants were offered cross-over to the
alternative strategy after the first syncope recurrence if no diagno-
sis was made.
Both the EaSyAS (Farwell 2006) andEaSyAS II (Sulke 2015) stud-
ies showed significant reductions in syncope recurrence after treat-
ment. Farwell 2006 demonstrated similar rates of second syncope
(between groups) up to about 300 days from randomisation; at
this point, the curves diverge with a reduction in the rate of further
events in the ILR group (P = 0.04). Sulke 2015 confirmed that
ILR participants were less likely to have a second post-randomi-
sation syncope compared with conventionally managed patients
(i.e. both the syncope clinic and conventional management arms)
(HR 0.38, 95% CI 0.17 to 0.86, P = 0.02).
Due to the differences in the way data were reported, we could
not perform a formal meta-analysis for this outcome.
Economic costs
Two trials analysed the cost implication of a diagnostic strategy
based on either ILR or conventional management (Farwell 2006;
Krahn 2001).
Farwell 2006, which was carried out in the UK, based costs in-
curred by further hospital admission and investigations for syn-
cope, calculated from time of device implantation to the study’s
conclusion, on local National Health Service (NHS) costs. They
did not include the cost of the ILR in the analysis, but the study
authors stated that ILR UK list price at the time of the study
was GBP 1350. Overall mean costs (including hospital stay) were
lower in the ILR group (GBP 820, median GBP 0, interquartile
range (IQR) GBP 0-200) than in the conventional management
group (GBP 1380, median GBP 100, IQR GBP 0-800), without
statistical significance (mean difference GBP 555, 95% CI GBP
252 to GBP 1990, P = 0.28).
Krahn 2001 calculated the costs of investigations based on the
Ontario Health Insurance Program fee schedule for technical
and professional fees and also included an estimate of materials,
labour, maintenance, and overheads for hospital-based investiga-
tions. They considered all costs to be direct medical costs that
were assessed from a societal perspective and expressed in 2002
Canadian Dollars (CAD). The mean cost of a primary strategy of
monitoring was CAD 2731 ± CAD 285, and the cost per diagno-
sis was CAD 5852 ± CAD 610. The cost of the investigation with
the conventional strategy was significantly less than investigation
with the primary strategy of monitoring (CAD 1683 ± CAD 505,
P < 0.0001) but the cost per diagnosis was significantly greater
(CAD 8414 ± CAD 2527, P < 0.0001).
Given the difficulty in comparing data from different health care
settings and the high heterogeneity in both the results and the
cost-assessments across the studies, we were unable to perform a
quantitative analysis. In order to give a comparable estimate across
the studies, we added the ILR cost (GPB 1350) to the first study’s
ILR group, we converted the mean cost per participant to Euros
(at the exchange rate on 16 October 2015) and we calculated:
1. mean costs per diagnosis;
2. mean costs per arrhythmic diagnosis; and
3. mean costs per diagnosis requiring invasive procedures (i.e.
permanent pacemaker or implantable cardioverter defibrillator
placement or catheter ablation).
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We have reported the results in Table 1. Please note: these results
are approximate and readers should interpret the data only by
comparing the two randomised groups within a single study.
Aetiological diagnosis
All the trials (579 participants) reported data on aetiological di-
agnosis. The mean duration of follow-up ranged from one year
(Krahn 2001) to 20 months (Sulke 2015).
Overall, there was a significant difference in the number of diag-
noses between participants who received ILR and those who were
managed conventionally at long-term follow-up (137/292 versus
36/287; RR (in favour of ILR) 0.61, 95%CI 0.54 to 0.68; partici-
pants = 579; studies = 4; moderate quality evidence), as compared
to participants in the standard assessment group, with no evidence
of heterogeneity. (Analysis 1.2; Figure 5).
Figure 5. Forest plot of comparison: 1 ILR vs SA, outcome: 1.2 Diagnosis.
D I S C U S S I O N
Summary of main results
Observational and case-control studies have shown that loop
recorders lead to earlier diagnosis and reduce the rate of unex-
plained syncope (Brignole 2006; EGSYS-2 2006; Krahn 1999;
Krahn 2004). However, only RCTs showing benefit on a primary
outcome of specific ILR-guided diagnosis and therapy, rather than
simply ECG diagnosis, should significantly change clinical prac-
tice. Therefore our review focusedmainly onmortality and quality
of life, as well as on diagnosis and syncope recurrence, which are
their surrogate end-points.
We only identified four studies, incorporating 579 participants.
The primary outcomes for all the included studies were the as-
sessment of the diagnostic yield of ILR compared to the standard
assessment commonly used by the referring physician, as well as
intensive diagnostic strategy performed in the context of a syncope
unit. None of the included studies had considered either mortality
or major adverse events as primary outcomes.
Due to the small number of included studies and the difference
in the endpoint assessment between the studies, we were able to
meta-analyse only two outcomes: mortality and aetiological di-
agnosis. Regarding the other four considered endpoints (adverse
events, quality of life, syncope recurrence and costs), only a qual-
itative analysis was possible (Summary of findings for the main
comparison).
We found no significant differences in reducing overall long-term
mortality. The strength of this statement has some limitations:
data on mortality were available only from two studies and were
mainly driven by the largest. Moreover, none of the studies had
been designed to assess mortality, as this is relatively uncommon
in unexplained syncope patients.
There were no complications following the ILR implant in the
studies analysing this outcome.
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The included trials seemed to show no difference in quality of life.
Since only two studies reported data on this outcome and used
different quality of life assessments (scores, length of follow-up,
data reporting) this finding is not conclusive.
Data from two studies seemed to show a trend towards a reduc-
tion in syncope relapses after diagnosis in participants implanted
with ILR. Again, the paucity of data does not allow us to derive
definitive conclusions.
Cost analyses showed highermean costs in the ILR groupwhen the
ILR cost is counted. However the cost per diagnosis and the cost
to diagnose an arrhythmia were lower for participants randomised
to ILR implant. To interpret these data we have to remember that
the ILR cost-effectiveness depends on both the population selected
and the kind of diagnoses we are interested in. Indeed, if ILRs are
used in a population at a high risk of recurrence (such as people
with vasovagal syncope), we could paradoxically observe a very
high diagnostic rate and hence a low cost per diagnosis. However,
when implanting an ILR, we are usually interested in diagnosing
potentially dangerous and treatable diseases, rather than benign
conditions. Moreover, length of follow-up might influence costs,
as a higher early expense due to the cost of ILR itself might be
balanced by a lower need for tests and hospital admissions in the
long term. Finally, we did not analyse the influence of an ILR-
directed treatment on further costs.
Participants who underwent ILR implantation experienced higher
rates of ECGdiagnosis, as compared toparticipants in the standard
assessment group.
Overall completeness and applicability of
evidence
Our review identified only four studies addressing the benefits and
harms of loop recorder implants in people with unexplained syn-
cope randomised to either ILRor conventional diagnostic workup.
The primary outcomes we were interested in were mortality, ad-
verse events and quality of life. Syncope relapse, costs and aetio-
logical diagnosis were secondary outcomes.
The studies were published from 2001 to 2015. One of them
was conducted in Canada and three in Europe; all of them were
single centre studies. Mean follow-up ranged from one year to 20
months.
The number of participants enrolled in each study varied between
60 and 246. The percentage of men in each study varied between
40 and 55, and the mean age of the population recruited varied
between 66 and 74 years.
The generalisability of the results of this review might be limited,
as the included studies were conducted in tertiary care centres.
Since the diagnostic strategy of participants in the conventional
management arm was almost always left to the referring physician,
participants referred to centres with a different expertise on syn-
cope might have different outcomes. Moreover all the available lit-
erature comes from Western countries, thus limiting the external
validity.
The data were sufficient to comment on aetiological diagnosis and
mortality, although we must acknowledge two limitations in the
interpretation of the latter. First, death was a relatively uncommon
event and none of the included trials was designed and powered
to assess it; second, long-term mortality might be influenced by
conditions unrelated to syncope. Therefore ILR implant seems to
result in a higher number of diagnoses without affecting long-term
mortality.
There were insufficient data to comment on the quality of life,
cost analysis and ability to prevent recurrences of ILR versus con-
ventional management in people with unexplained syncope. The
outcomes of quality of life, costs and adverse events are important
clinical endpoints to consider when deciding the best diagnostic
strategy for people with unexplained syncope.
Quality of the evidence
The trials had a high risk of performance bias and detection bias
due to the lack of blinding. These limitations may lead to an over-
estimation of the effect of ILR over conventional management,
but are difficult to quantify and to overcome, as the intervention
requires an invasive procedure and post-implant management and
follow-up.
We used the GRADE methodology in order to assess the quality
of the body of evidence for the prespecified outcomes. There was
a very low quality of evidence in our primary outcome, all-cause
mortality, and a moderate quality of evidence in the secondary
outcome of diagnostic rate.
Potential biases in the review process
We used a prespecified protocol for our review and complemented
our search of published literature with handsearching and contact-
ing study authors. We consider that there was a high likelihood
that we included all published studies. However, since there were
few published studies, we could not perform a formal assessment
of publication bias. We followed guidelines from the Cochrane
Handbook for Systematic Reviews of Interventions to perform our
title screening and data extraction tominimise bias and believe the
review process has a low risk of introducing bias (Higgins 2011a).
Agreements and disagreements with other
studies or reviews
Toour knowledge, there are noother systematic reviews comparing
RCTs of ILR versus conventional diagnostic strategies in people
with unexplained syncope. A previous narrative review (Parry
2010) reported data from observational and case-control studies
showing that loop recorders lead to earlier diagnosis and reduce the
rate of unexplained syncope. However, both the studies included
and the review focused mainly on the ability of ILR to reach a
diagnosis rather than to change patients’ outcomes or quality of
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life.Moreover, even if a systematic literature searchwas performed,
no attempt to combine the available data was made.
Interestingly, despite this lack of conclusive evidence on the util-
ity of ILR in the diagnostic strategy of syncope, the ESC (Moya
2009) and European Heart Rhythm Association 2009 guidelines
(Brignole 2009) recommend that ILRs are implanted in the early
phase of evaluation of patients with recurrent syncope of uncertain
origin in the absence of high-risk criteria, and in high-risk patients
after a negative evaluation (Class IB and IA, respectively). This
could be the consequence of the fact that clinicians are muchmore
confident when the ECG registration during symptoms is avail-
able. However, a higher diagnostic rate does not necessarily lead
to a better outcome or a higher quality of life and more evidence
is needed before ILR implant will be routinely recommended in
people with unexplained syncope.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our systematic review shows that there is no evidence that an ILR-
based diagnostic strategy reduces long-termmortality as compared
to a standard diagnostic assessment (very low quality evidence).
No data were available for short-term all-cause mortality. Moder-
ate quality evidence shows that an ILR-based diagnostic strategy
increases the rate of aetiologic diagnosis compared to a standard
diagnostic pathway. No conclusive data were available on the other
end-points analysed.
Currently there is no strong evidence that an ILR-based diagnostic
strategy might change patient-centred outcomes like mortality,
adverse events, quality of life and syncope relapses.
Implications for research
Further trials evaluating the effect of ILRs in the diagnostic strat-
egy of people with recurrent unexplained syncope are warranted.
Future research should focus on the assessment of the ability of
ILRs to change clinically relevant outcomes besides increasing the
diagnostic rate. Cost analysis should include both costs for achiev-
ing the diagnosis and those incurred by further hospital admission
and events following aetiologic treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Farwell 2006
Methods Randomised clinical trial
Participants Consecutive patients with recurrent syncope (i.e. two or more episodes in the past year)
and without a definite diagnosis following initial clinical workup (comprising history
and a physical examination, 12-lead ECG, full blood count, urea and electrolytes, plasma
glucose and Holter monitoring in the patients with suspected cardiac syncope)
103 participants randomised to ILR; 98 participants randomised to conventional man-
agement
46% men
Median (IQ range) age: 74 (61-81) years
Two participants in the ILR group and one participant in the conventional management
group were reported as lost to follow-up
Interventions Group 1: Medtronic Reveal Plus ILR
Group 2: conventional management
Outcomes Primary: Time to ECG diagnosis
Secondary: (1) Time to first recurrence of syncope following study induction. (2) Time
to second recurrence of syncope following study induction. (3) Time to the introduction
of ECG-guided therapy
Tertiary: (1) Quality of life. Measured by SF-12 questionnaire and visual analogue scales
(VAS) at induction, 6, 12, and 18 months post-enrolment. (2) Cost effectiveness
Even if they were not study outcomes, data on long-term mortality and adverse events
were also available
Mean follow-up 17 months
Notes Eastbourne Syncope Assessment Study (EaSyAS)
The study was partly supported by grants from Medtronic UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was by random number tables
Allocation concealment (selection bias) Low risk Participants were allocated by sealed envelopes held in the
study centre
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither participants nor personnel were blinded to the in-
tervention or the control
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Farwell 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded to the intervention
group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers across interven-
tion groups
Selective reporting (reporting bias) Unclear risk The study protocol was not available
Krahn 2001
Methods Randomised cross-over clinical trial
Participants Recurrent unexplained syncope or a single episode of syncope associated with injury
that warranted cardiovascular investigation and without a definite diagnosis following
initial clinical workup (comprising postural blood pressure testing, a minimum of 24
hours of baseline ambulatory monitoring or inpatient telemetry, and a transthoracic
echocardiogram)
30 participants randomised to ILR; 30 participants randomised to conventional man-
agement
55% men
Mean (SD) age: 66 (14) years
Three participants in the ILR group were still in follow-up at the time of the paper
publication, therefore only 27 participants were analysed in the ILR population. The cost
analysis (which was published two years later) included all the randomised participants
Interventions Group 1: Medtronic Reveal ILR
Group 2: a two- to four-week period of monitoring with an external loop recorder,
followed by tilt table, and electrophysiological testing
If the assigned strategy did not provide a diagnosis, participants were offered cross-over
to the alternate strategy (for the purpose of our review only the primary strategy was
considered)
Outcomes Symptom-rhythm correlation (diagnostic yield) in participants during spontaneous syn-
cope or presyncope that resembled the symptoms before enrolment
Even if they were not study outcomes, data on long-term mortality, syncope recurrence
and costs were also available
Mean follow-up 12 months
Notes Randomized Assessment of Syncope Trial (RAST)
This study was supported by a grant from the Heart and Stroke Foundation of Ontario
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not reported
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Krahn 2001 (Continued)
Allocation concealment (selection bias) Unclear risk Allocation concealment from study members not
reported, but the characteristics of each group
were similar at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It does not appear that either participants or per-
sonnel were blinded to the intervention or the
control
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded to the inter-
vention group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk It does not appear that any participants were lost
to follow-up, however three participants in the
ILR group were still in follow-up at the time that
one of the reports was published
Selective reporting (reporting bias) Unclear risk The study protocol was not available
Podoleanu 2014
Methods Randomised clinical trial
Participants Patients from the hospitalisation ward or outpatient department who presented with one
of the following criteria: a single syncope, if severe (i.e.not preceded by prodrome, which
resulted in an injury) and recent (i.e. occurring within the previous six months); or at
least two syncopes in the past 12 months. The syncope had to remain unexplained at the
end of the clinical examination, and after performing a 12-lead electrocardiogram (ECG)
, echocardiography and head-up tilt-test, meaning that a further diagnostic workup was
mandatory
39 participants randomised to ILR; 39 participants randomised to conventional man-
agement
41% men
Mean (SD) age: 66.2 (14.8) years
No participants were reported as lost to follow-up
Interventions Group 1: Medtronic Reveal or Reveal Plus ILR
Group 2: conventional evaluation strategy commonly used by the attending physician
Outcomes Diagnostic yield, cost and impact on quality of life
Mean follow-up 14 months
Notes French Study on implantable Holter Recorders in Syncope (FRESH)
This study received a grant from the Société Francaise de Cardiologie
Risk of bias
Bias Authors’ judgement Support for judgement
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Podoleanu 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Unclear risk Allocation concealment from study members not reported,
but the characteristics of each group were similar at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither participants nor personnel were blinded to the in-
tervention or the control
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded to the intervention
group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participant was lost to follow-up
Selective reporting (reporting bias) High risk Although cost analysis is one of the study’s aims, its results
were not reported
Sulke 2015
Methods Randomised clinical trial
Participants Participants presented to the emergency department, to general practitioners in the
community as well as to medical, surgical, and orthopaedic wards with a diagnosis of
recurrent syncope (at least two syncopes in the past 24 months)
66 participants randomised to ILR only; 59 participants randomised to ILR and syncope
clinic; 60 participants randomised to syncope clinic only; 61 participants randomised to
conventional management
40.2% men
Mean (SD) age: 70.3 (18) years.
Five participants withdrew from the study following enrolment. Four declined to ac-
cept ILR implantation. One participant required regular MRI scans for surveillance of
a benign brain tumour, so declined the ILR despite the fact that the Sleuth is MR-
conditional. One participant requested to have his ILR explanted at eight months due
to intolerance
Interventions Group 1: Transoma Sleuth ILR
Group 2: Transoma Sleuth ILR and syncope clinic
Group 3: syncope clinic
Group 4: conventional evaluation strategy commonly used by the referring physician
Outcomes Primary: time to ECG diagnosis
Secondary: time to first and second post-randomisation syncope, and time to ECG-
directed therapy
Even if they were not study outcomes, data on adverse events were also available
Mediam follow-up 20.4 months
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Sulke 2015 (Continued)
Notes Eastbourne Syncope Assessment Study II (EaSyAS II)
The study was part funded by an unrestricted grant from Transoma Medical Inc. The
majority of funding was from the Eastbourne Cardiology Research Charity Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number tables
Allocation concealment (selection bias) Unclear risk Allocation concealment from study members not reported,
but the characteristics of each group were similar at baseline
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither participants nor personnel were blinded to the in-
tervention or the control
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not blinded to the intervention
group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing outcome data unlikely to be related
to true outcome: 5 participants withdrew from the study
following enrolment (declined to accept ILR implantation)
, 1 participant requested to have his ILR explanted at eight
months due to intolerance
Selective reporting (reporting bias) High risk Although cost analysis is one of the study’s aims, its results
were not reported
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Da Costa 2013 Only patients with ECG abnormalities were included
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D A T A A N D A N A L Y S E S
Comparison 1. ILR vs SA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 2 255 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.41, 2.30]
2 Diagnosis 4 579 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.54, 0.68]
Analysis 1.1. Comparison 1 ILR vs SA, Outcome 1 All-cause mortality.
Review: Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope
Comparison: 1 ILR vs SA
Outcome: 1 All-cause mortality
Study or subgroup ILR
Standard
assessment
(SA) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Farwell 2006 8/101 9/97 95.1 % 0.85 [ 0.34, 2.12 ]
Krahn 2001 1/27 0/30 4.9 % 3.32 [ 0.14, 78.25 ]
Total (95% CI) 128 127 100.0 % 0.97 [ 0.41, 2.30 ]
Total events: 9 (ILR), 9 (Standard assessment (SA))
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ILR Favours SA
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Analysis 1.2. Comparison 1 ILR vs SA, Outcome 2 Diagnosis.
Review: Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope
Comparison: 1 ILR vs SA
Outcome: 2 Diagnosis
Study or subgroup ILR
Standard
assessment
(SA)
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Podoleanu 2014 18/39 2/39 14.6 % 0.57 [ 0.42, 0.77 ]
Krahn 2001 14/27 6/30 9.0 % 0.60 [ 0.39, 0.93 ]
Sulke 2015 62/125 21/121 40.1 % 0.61 [ 0.50, 0.74 ]
Farwell 2006 43/101 7/97 36.3 % 0.62 [ 0.52, 0.74 ]
Total (95% CI) 292 287 100.0 % 0.61 [ 0.54, 0.68 ]
Total events: 137 (ILR), 36 (Standard assessment (SA))
Heterogeneity: Chi2 = 0.24, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 8.46 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours ILR Favours SA
A D D I T I O N A L T A B L E S
Table 1. Cost analysis
Farwell 2006 Krahn 2001
ILR SA ILR SA
Number of participants 101 97 30 30
Mean follow-up
(months)
17 12
Mean cost (SD) per par-
ticipant
GBP 2170 GBP 1380 CAD 2731 (285) CAD 1683 (505)
Median cost (IQR) per
participant
GBP 1350 (1350-1550) GBP 1480 (0-800)
Mean cost per partici-
pant
EUR 2952 EUR 1877 EUR 1863 EUR 1148
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Table 1. Cost analysis (Continued)
Number of diagnoses 43 7 14 6
Number of arrhythmic
diagnoses
20 4 11 4
Number of diagnoses re-
quiring invasive proce-
dures
17 4 11 4
Mean cost per diagnosis EUR 6934 EUR 26010 EUR 3992 EUR 5740
Mean cost per arrhyth-
mic diagnosis
EUR 14908 EUR 45517 EUR 5081 EUR 8610
Mean cost per diagnosis
requiring invasive proce-
dures
EUR 17538 EUR 45517 EUR 5081 EUR 8610
CAD: Canadian Dollars; EUR: Euros; GBP: GB Pounds; ILR: Implantable Loop Recorder; IQR: interquartile range; SA: standard
assessment; SD: standard deviation.
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL
#1 MeSH descriptor: [Syncope] explode all trees
#2 syncop*:ti,ab,kw (Word variations have been searched)
#3 presyncop*:ti,ab,kw (Word variations have been searched)
#4 faint*:ti,ab,kw (Word variations have been searched)
#5 lipothymi*:ti,ab,kw (Word variations have been searched)
#6 MeSH descriptor: [Dizziness] this term only
#7 dizzy*:ti,ab,kw (Word variations have been searched)
#8 dizzi*:ti,ab,kw (Word variations have been searched)
#9 light headedness:ti,ab,kw (Word variations have been searched)
#10 light-headedness:ti,ab,kw (Word variations have been searched)
#11 lightheadedness:ti,ab,kw (Word variations have been searched)
#12 orthostasis:ti,ab,kw (Word variations have been searched)
#13 drop attack*:ti,ab,kw (Word variations have been searched)
#14 MeSH descriptor: [Unconsciousness] this term only
#15 unconscious*:ti,ab,kw (Word variations have been searched)
#16 loss of consciou*:ti,ab,kw (Word variations have been searched)
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 MeSH descriptor: [Electrocardiography, Ambulatory] this term only
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#19 MeSH descriptor: [Electrocardiography] this term only
#20 loop recorder*:ti,ab,kw (Word variations have been searched)
#21 ilr*:ti,ab,kw (Word variations have been searched)
#22 (implant* near/5 (ecg or electrocardiog*)):ti,ab,kw (Word variations have been searched)
#23 ((implant* or internal or event*) near/2 record*):ti,ab,kw (Word variations have been searched)
#24 confirm:ti,ab,kw (Word variations have been searched)
#25 reveal:ti,ab,kw (Word variations have been searched)
#26 sleuth:ti,ab,kw (Word variations have been searched)
#27 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
#28 #17 and #27
MEDLINE OVID
1. exp Syncope/
2. syncop*.tw.
3. presyncop*.tw.
4. faint*.tw.
5. lipothymi*.tw.
6. Dizziness/
7. dizzy*.tw.
8. dizzi*.tw.
9. light headedness.tw.
10. light-headedness.tw.
11. lightheadedness.tw.
12. orthostasis.tw.
13. drop attack*.tw.
14. Unconsciousness/
15. unconscious*.tw.
16. loss of consciou*.tw.
17. or/1-16
18. Electrocardiography, Ambulatory/
19. Electrocardiography/
20. loop recorder*.tw.
21. ilr*.tw.
22. (implant* adj5 (ecg or electrocardiog*)).tw.
23. ((implant* or internal or event*) adj2 record*).tw.
24. confirm.tw.
25. reveal.tw.
26. sleuth.tw.
27. or/18-26
28. 17 and 27
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.
31. randomized.ab.
32. placebo.ab.
33. drug therapy.fs.
34. randomly.ab.
35. trial.ab.
36. groups.ab.
37. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. exp animals/ not humans.sh.
39. 37 not 38
40. 28 and 39
33Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
EMBASE OVID
1. exp Faintness/
2. syncop*.tw.
3. presyncop*.tw.
4. faint*.tw.
5. lipothymi*.tw.
6. Dizziness/
7. dizzy*.tw.
8. dizzi*.tw.
9. light headedness.tw.
10. light-headedness.tw.
11. lightheadedness.tw.
12. orthostasis.tw.
13. drop attack*.tw.
14. Unconsciousness/
15. unconscious*.tw.
16. loss of consciou*.tw.
17. or/1-16
18. Electrocardiography/
19. loop recorder*.tw.
20. ilr*.tw.
21. (implant* adj5 (ecg or electrocardiog*)).tw.
22. ((implant* or internal or event*) adj2 record*).tw.
23. confirm.tw.
24. reveal.tw.
25. sleuth.tw.
26. or/18-25
27. 17 and 26
28. random$.tw.
29. factorial$.tw.
30. crossover$.tw.
31. cross over$.tw.
32. cross-over$.tw.
33. placebo$.tw.
34. (doubl$ adj blind$).tw.
35. (singl$ adj blind$).tw.
36. assign$.tw.
37. allocat$.tw.
38. volunteer$.tw.
39. crossover procedure/
40. double blind procedure/
41. randomized controlled trial/
42. single blind procedure/
43. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42
44. (animal/ or nonhuman/) not human/
45. 43 not 44
46. 27 and 45
ClinicalTrials.gov
syncope AND Implantable Loop Recorders
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World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal
syncope AND Implantable Loop Recorders
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
After the protocol was published, we realised that ILR-related complications needed to be considered as adverse events, so we added
them as primary outcomes if participants needed either ILR explantation or treatment.
In the published protocol, we had anticipated that we would search all databases from 1990 as ILRs were introduced into clinical
practice in the 1990s. In order to be more sensitive we conducted the searches from the earliest date available in each database instead.
In contrast with what we had planned, we included a cross-over trial. Cross-over designs may represent a problem when analysed
together with parallel group trials in systematic reviews (Higgins 2011c). For example, cross-over trials may have shorter intervention
periods or may include participants with less severe illness. Also, a problem associated with them is that of carry-over (a type of period-
by-intervention interaction). Carry-over is the situation in which the effects of an intervention given in one period persist into a
subsequent period, thus interfering with the effects of a different subsequent intervention. One of the studies we identified reported
data from a cross-over trial (Krahn 2001). However, as intervention periods, participants’ characteristics and type of interventions and
controls were similar to those of the other studies selected, we decided to include it in the review. Since carry-over could be an issue
in this case (mortality and diagnosis are irreversible), as suggested in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011c), we included only data from the first period.
Differently from what we had planned in the protocol and according to the suggestions of the Cochrane Handbook for Systematic Reviews
of Interventions (Deeks 2011), as no heterogeneity was found we used a fixed-effect rather than a random-effects model.
We have included a ’Summary of findings’ table (Schünemann 2011a) and GRADE assessment (Schünemann 2011b) to comply with
the latest Cochrane requirements.
We defined mixed age populations as > 80% of participants are required to be 18 years or older.
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